Summary:
The majority of patients with hepatitis A have a benign course, but some may develop fulminant hepatitis and hematological complications. Peripheral stem cell transplantation (PSCT) is associated with loss of immunity. There are no data regarding loss of HAV antibodies (anti-HAV) after PSCT. We retrospectively evaluated the persistence of anti-HAV in a nonvaccinated population that underwent PSCT. Serum detection of anti-HAV was determined before and after PSCT using a qualitative commercially available enzyme immunoassay. From January 1997 to March 2001, 136 (68%) of 201 patients tested (+) for anti-HAV prior to PSCT. Subsequent investigation of anti-HAV was possible in 36 of these patients at a median of 12 months after PSCT. The median age of patients was 47 years old; they had diagnoses of hematological malignancies (33) and solid tumors (three), and underwent autologous (31) and allogenic (five) PSCT. A total of 31 (86%) of 36 patients remained anti-HAV (+) and five (14%) became (−) after PSCT. The variables age, sex, diagnosis, type of PSCT, time of testing, and number of CD34 cells infused were not predictors of loss of anti-HAV. In conclusion, 14% of 36 nonvaccinated anti-HAV (+) patients lost their antibodies at a median of 12 months after PSCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Palmovic D, Kosutic Z, Puntaric V . Transient hypoplasia of granulocyte stem cells during viral hepatitis A. Lijecnicki Vjesnik 1984; 106: 294–296.
Kusaba N, Yoshida H, Ohkubo F et al. Autoimmune thrombocytopenia and erythroid hypoplasia associated with hepatitis A. Rinsho Ketsueki — Jpn J Clin Hematol 2000; 41: 739–744.
Ibarra H, Zapata C, Inostroza J et al. Immune thrombocytopenic purpura associated with hepatitis A. Blut 1986; 52: 371–375.
Aoyagi K, Ohhara N, Okamura S et al. Aplastic anemia associated with type A viral hepatitis—possible role of T-lymphocytes. Jpn J Med 1987; 26: 348–352.
Maiga MY, Oberti F, Rifflet H et al. Hematological manifestations related to hepatitis A virus. 3 cases. Gastroenterol Clin Biol 1997; 21: 327–330.
Tomida S, Matsuzaki Y, Nishi M et al. Severe acute hepatitis A associated with acute pure red cell aplasia. J Gastroenterol 1996; 31: 612–617.
Hara K, Tagawa K, Unuma T . Acute hemolysis associated with hepatitis A. Gastroenterolo Japon 1985; 20: 611–615.
Khouri K, Boujaoude J, Chahine G et al. Bone marrow aplasia complicating viral hepatitis A with significant cholestasis: a case report. Gastroenterol Clini Biol 1998; 22: 559–560.
Ciocca M . Clinical course and consequences of hepatitis A infection. Vaccine. 2000; 18: S71–S74.
Arslan M, Wiesner RH, Poterucha JJ et al. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transplant 2000; 6: 191–195.
Pauksen K, Hammarstrom V, Ljungman P et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994; 18: 547–552.
Pauksen K, Duraj V, Ljungman P et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplant Bone Marrow Transplant 1992; 9: 427–432.
Hammarstrom V, Pauksen K, Bjorkstrand B et al. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant 1998; 22: 67–71.
Frixos P, B Lymphocytes. In: Ricchard L (ed.). Wintrobe's Clinical Hematology, Vol. 1, 10th edn. Lippincott Williams & Wilkins: Baltimore, MD, 1999; pp 464–496.
Lopez H, Zitto T, Bare P et al. Prevalence of anti-hepatitis A antibodies in an urban middle class area of Argentina: some associated factors. Int J Infect Dis 2000; 4: 34–37.
Fujiyama S, Odoh K, Kuramoto I et al. Current seroepidemiological status of hepatitis A with a comparison of antibody titers after infection and vaccination. J Hepatol 1994; 21: 641–645.
Ramonet M, Ciocca M, Nunez MH et al. Etiologia de la hepatitis viral aguda en una poblacion pediatrica. Medicina (B Aires) 1985; 45: 273–278.
Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48: 1–37.
Pebody RG, Leino T, Ruutu P et al. Foodborne outbreaks of hepatitis A in a low endemic country: an emerging problem? Epidemiol Infect 1998; 120: 55–59.
Ukkonen P, Pettersson R, Halonen P . Hepatitis A antibodies in Finland. Scand J Infect Dis 1979; 11: 311–312.
Bell BP, Shapiro CN, Alter NJ et al. The diverse patterns of hepatitis A epidemiology in the United States—implications for vaccination strategies. J Infect Dis 1998; 178: 1579–1584.
Centers for Disease Control and Prevention. Hepatitis Surveillance. US Department of Health and Human Services, Public Health Service: Atlanta, GA, 1996.
Arslan M, Wiesner RH, Poterucha JJ et al. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72: 272–276.
Neilsen GA, Bodsworth NJ, Watts N . Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997; 176: 1064–1067.
Tilzey AJ, Palmer SJ, Harrington C et al. Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996; 14: 1039–1041.
Hess G, Clemens R, Bienzle U et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995; 46: 40–42.
Santagostino E, Gringeri A, Rocino A et al. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemostasis 1994; 72: 508–510.
Acknowledgements
We thank Carla Longobardi, Claudia Borgadelli, Silvia Rogel, Mónica Covatti and Mariana Juni (Fundaleu, Buenos Aires, Argentina) for their technical support in this study, and Dr Elias Anaissie (Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock, Arkansas) for his critical review.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dignani, M., Miceli, M., Rosa, C. et al. Loss of hepatitis A virus (HAV) antibodies after peripheral stem cell transplantation (PSCT). Bone Marrow Transplant 31, 809–812 (2003). https://doi.org/10.1038/sj.bmt.1704028
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704028
Keywords
This article is cited by
-
Significant loss of hepatitis A Ab after allogeneic hematopoietic SCT in pediatric patients
Bone Marrow Transplantation (2010)
-
Loss of hepatitis A virus antibodies after bone marrow transplantation
Bone Marrow Transplantation (2006)